Literature DB >> 26491156

Development and Characterization of a Guinea Pig-Adapted Sudan Virus.

Gary Wong1, Shihua He2, Haiyan Wei3, Andrea Kroeker1, Jonathan Audet1, Anders Leung2, Todd Cutts4, Jill Graham5, Darwyn Kobasa1, Carissa Embury-Hyatt5, Gary P Kobinger6, Xiangguo Qiu7.   

Abstract

UNLABELLED: Infections with Sudan virus (SUDV), a member of the genus Ebolavirus, result in a severe hemorrhagic fever with a fatal outcome in over 50% of human cases. The paucity of prophylactics and therapeutics against SUDV is attributed to the lack of a small-animal model to screen promising compounds. By repeatedly passaging SUDV within the livers and spleens of guinea pigs in vivo, a guinea pig-adapted SUDV variant (SUDV-GA) uniformly lethal to these animals, with a 50% lethal dose (LD50) of 5.3 × 10(-2) 50% tissue culture infective doses (TCID50), was developed. Animals infected with SUDV-GA developed high viremia and died between 9 and 14 days postinfection. Several hallmarks of SUDV infection, including lymphadenopathy, increased liver enzyme activities, and coagulation abnormalities, were observed. Virological analyses and gross pathology, histopathology, and immunohistochemistry findings indicate that SUDV-GA replicates in the livers and spleens of infected animals similarly to SUDV infections in nonhuman primates. These developments will accelerate the development of specific medical countermeasures in preparation for a future disease outbreak due to SUDV. IMPORTANCE: A disease outbreak due to Ebola virus (EBOV), suspected to have emerged during December 2013 in Guinea, with over 11,000 dead and 28,000 infected, is finally winding down. Experimental EBOV vaccines and treatments were administered to patients under compassionate circumstances with promising results, and availability of an approved countermeasure appears to be close. However, the same range of experimental candidates against a potential disease outbreak caused by other members of the genus Ebolavirus, such as Sudan virus (SUDV), is not readily available. One bottleneck contributing to this situation is the lack of a small-animal model to screen promising drugs in an efficient and economical manner. To address this, we have generated a SUDV variant (SUDV-GA) that is uniformly lethal to guinea pigs. Animals infected with SUDV-GA develop disease similar to that of SUDV-infected humans and monkeys. We believe that this model will significantly accelerate the development of life-saving measures against SUDV infections.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26491156      PMCID: PMC4702555          DOI: 10.1128/JVI.02331-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations.

Authors:  Jens H Kuhn; Stephan Becker; Hideki Ebihara; Thomas W Geisbert; Karl M Johnson; Yoshihiro Kawaoka; W Ian Lipkin; Ana I Negredo; Sergey V Netesov; Stuart T Nichol; Gustavo Palacios; Clarence J Peters; Antonio Tenorio; Viktor E Volchkov; Peter B Jahrling
Journal:  Arch Virol       Date:  2010-10-30       Impact factor: 2.574

Review 2.  Industrialization of mAb production technology: the bioprocessing industry at a crossroads.

Authors:  Brian Kelley
Journal:  MAbs       Date:  2009-09-16       Impact factor: 5.857

3.  Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team.

Authors: 
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

4.  Ebola haemorrhagic fever in Zaire, 1976.

Authors: 
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

5.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Authors:  Steven M Jones; Heinz Feldmann; Ute Ströher; Joan B Geisbert; Lisa Fernando; Allen Grolla; Hans-Dieter Klenk; Nancy J Sullivan; Viktor E Volchkov; Elizabeth A Fritz; Kathleen M Daddario; Lisa E Hensley; Peter B Jahrling; Thomas W Geisbert
Journal:  Nat Med       Date:  2005-06-05       Impact factor: 53.440

6.  Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.

Authors:  William D Pratt; Danher Wang; Donald K Nichols; Min Luo; Jan Woraratanadharm; John M Dye; David H Holman; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2010-02-24

7.  A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

Authors:  M Bray; K Davis; T Geisbert; C Schmaljohn; J Huggins
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

8.  Pathogenesis of experimental Ebola virus infection in guinea pigs.

Authors:  B M Connolly; K E Steele; K J Davis; T W Geisbert; W M Kell; N K Jaax; P B Jahrling
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

9.  Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.

Authors:  Thomas W Geisbert; Kathleen M Daddario-DiCaprio; Kinola J N Williams; Joan B Geisbert; Anders Leung; Friederike Feldmann; Lisa E Hensley; Heinz Feldmann; Steven M Jones
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

10.  Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.

Authors:  Thomas W Geisbert; Joan B Geisbert; Anders Leung; Kathleen M Daddario-DiCaprio; Lisa E Hensley; Allen Grolla; Heinz Feldmann
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

View more
  22 in total

1.  Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors:  J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.

Authors:  Zachary A Bornholdt; Andrew S Herbert; Chad E Mire; Shihua He; Robert W Cross; Anna Z Wec; Dafna M Abelson; Joan B Geisbert; Rebekah M James; Md Niaz Rahim; Wenjun Zhu; Viktoriya Borisevich; Logan Banadyga; Bronwyn M Gunn; Krystle N Agans; Ariel S Wirchnianski; Eileen Goodwin; Kevin Tierney; William S Shestowsky; Ognian Bohorov; Natasha Bohorova; Jesus Velasco; Eric Ailor; Do Kim; Michael H Pauly; Kevin J Whaley; Galit Alter; Laura M Walker; Kartik Chandran; Larry Zeitlin; Xiangguo Qiu; Thomas W Geisbert; John M Dye
Journal:  Cell Host Microbe       Date:  2019-01-09       Impact factor: 21.023

3.  Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.

Authors:  Anna Z Wec; Zachary A Bornholdt; Shihua He; Andrew S Herbert; Eileen Goodwin; Ariel S Wirchnianski; Bronwyn M Gunn; Zirui Zhang; Wenjun Zhu; Guodong Liu; Dafna M Abelson; Crystal L Moyer; Rohit K Jangra; Rebekah M James; Russell R Bakken; Natasha Bohorova; Ognian Bohorov; Do H Kim; Michael H Pauly; Jesus Velasco; Robert H Bortz; Kevin J Whaley; Tracey Goldstein; Simon J Anthony; Galit Alter; Laura M Walker; John M Dye; Larry Zeitlin; Xiangguo Qiu; Kartik Chandran
Journal:  Cell Host Microbe       Date:  2019-01-09       Impact factor: 21.023

4.  Marburg and Ravn Virus Infections Do Not Cause Observable Disease in Ferrets.

Authors:  Gary Wong; Zirui Zhang; Shihua He; Marc-Antoine de La Vega; Kevin Tierney; Geoff Soule; Kaylie Tran; Lisa Fernando; Xiangguo Qiu
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

5.  Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease.

Authors:  Robert Kozak; Shihua He; Andrea Kroeker; Marc-Antoine de La Vega; Jonathan Audet; Gary Wong; Chantel Urfano; Kym Antonation; Carissa Embury-Hyatt; Gary P Kobinger; Xiangguo Qiu
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

Review 6.  Human immune system mouse models of Ebola virus infection.

Authors:  Jessica R Spengler; Joseph Prescott; Heinz Feldmann; Christina F Spiropoulou
Journal:  Curr Opin Virol       Date:  2017-08-12       Impact factor: 7.090

7.  Postexposure Protective Efficacy of T-705 (Favipiravir) Against Sudan Virus Infection in Guinea Pigs.

Authors:  Md N Rahim; Zirui Zhang; Shihua He; Wenjun Zhu; Logan Banadyga; David Safronetz; Xiangguo Qiu
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

8.  Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques.

Authors:  Courtney Woolsey; Alyssa C Fears; Viktoriya Borisevich; Krystle N Agans; Natalie S Dobias; Abhishek N Prasad; Daniel J Deer; Joan B Geisbert; Karla A Fenton; Thomas W Geisbert; Robert W Cross
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

Review 9.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

Review 10.  Rodent-Adapted Filoviruses and the Molecular Basis of Pathogenesis.

Authors:  Logan Banadyga; Michael A Dolan; Hideki Ebihara
Journal:  J Mol Biol       Date:  2016-05-14       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.